AR045727A1 - Fluorocombretastatina y derivados de la misma - Google Patents

Fluorocombretastatina y derivados de la misma

Info

Publication number
AR045727A1
AR045727A1 ARP040102519A ARP040102519A AR045727A1 AR 045727 A1 AR045727 A1 AR 045727A1 AR P040102519 A ARP040102519 A AR P040102519A AR P040102519 A ARP040102519 A AR P040102519A AR 045727 A1 AR045727 A1 AR 045727A1
Authority
AR
Argentina
Prior art keywords
same
fluorocombretastatina
derivatives
nhr
halogen
Prior art date
Application number
ARP040102519A
Other languages
English (en)
Inventor
Giuseppe Giannini
Mauro Marzi
Domenico Alloatti
Maria Ornella Tinti
Teresa Riccioni
Marcella Marcellini
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of AR045727A1 publication Critical patent/AR045727A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/84—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Procedimiento de preparación composición farmacéutica que los comprende y sus usos. Reivindicación 1: Un compuesto de fórmula (1), caracterizado porque: R1, R2 y R3, que pueden ser iguales o diferentes, son H, OMe, NO2, NHR'; X e Y, diferentes entre sí, son halógeno o H; Z = H o halógeno; R = OH, OPO3Na2, OCH2OPO3Na2, OR', NO2, NHR'; R' = H, alquilo (C1-6), (COCHR''NH)n-H; R'' = H, una cadena lateral de aminoácido, Ph; n es un entero comprendido entre 1 y 3; sus sales, racematos y enantiómeros simples farmacéuticamente aceptables.
ARP040102519A 2003-07-18 2004-07-16 Fluorocombretastatina y derivados de la misma AR045727A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0316910A GB2403949A (en) 2003-07-18 2003-07-18 Combretastatin derivatives

Publications (1)

Publication Number Publication Date
AR045727A1 true AR045727A1 (es) 2005-11-09

Family

ID=27764110

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102519A AR045727A1 (es) 2003-07-18 2004-07-16 Fluorocombretastatina y derivados de la misma

Country Status (13)

Country Link
US (1) US7572778B2 (es)
EP (1) EP2112990A2 (es)
JP (1) JP2007530428A (es)
KR (1) KR20060036458A (es)
CN (1) CN100522910C (es)
AR (1) AR045727A1 (es)
AU (1) AU2004257012B2 (es)
BR (1) BRPI0412656A (es)
CA (1) CA2531596A1 (es)
GB (1) GB2403949A (es)
MX (1) MXPA06000626A (es)
TW (1) TW200505420A (es)
WO (1) WO2005007603A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1976505A1 (en) * 2005-11-14 2008-10-08 Abraxis BioScience, Inc. Combretastatin derivatives and related therapeutic methods
CN101074189B (zh) * 2006-05-15 2011-04-13 雍智全 苯乙烯酸衍生物及其在制备血管靶向剂药物中的应用
CN101085743B (zh) 2006-06-06 2012-02-15 浙江大德药业集团有限公司 含氟烷氧基康普立停衍生物及制法和用途
CN101735265A (zh) * 2009-12-16 2010-06-16 陕西合成药业有限公司 用于治疗的抗肿瘤化合物
CN102249987B (zh) * 2011-05-06 2013-07-24 兰州大学 一种考布他汀类化合物及其制备方法和用途
CN103524349B (zh) * 2013-10-19 2015-09-09 山东大学 Ca-4碳酸酯类衍生物、其制备方法、药物组合物与医药用途
CN113577020B (zh) * 2021-08-16 2022-09-23 海南鑫开源医药科技有限公司 一种玻璃体腔内注射剂、其制备方法及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
EP1351912A2 (en) * 2000-12-21 2003-10-15 Cancer Research Ventures Limited Substituted stilbenes, their reactions and anticancer activity

Also Published As

Publication number Publication date
AU2004257012A1 (en) 2005-01-27
AU2004257012B2 (en) 2009-10-08
BRPI0412656A (pt) 2006-09-26
US20060160778A1 (en) 2006-07-20
EP2112990A2 (en) 2009-11-04
WO2005007603A2 (en) 2005-01-27
GB2403949A (en) 2005-01-19
CN1826308A (zh) 2006-08-30
WO2005007603A3 (en) 2005-07-07
TW200505420A (en) 2005-02-16
MXPA06000626A (es) 2006-04-19
CA2531596A1 (en) 2005-01-27
US7572778B2 (en) 2009-08-11
JP2007530428A (ja) 2007-11-01
CN100522910C (zh) 2009-08-05
GB0316910D0 (en) 2003-08-20
KR20060036458A (ko) 2006-04-28

Similar Documents

Publication Publication Date Title
DK1542997T3 (da) Pyrazolylbenzothiazolderivater og deres anvendelse som terapeutiske midler
LU92433I2 (fr) Olodatérol, ses isomères optiques individuels, mélanges d'énantiomères individuels ou de racémates, ses sels d'addition d'acide avec des acides pharmaceutiquement acceptables, ainsi que ses solvates et/ou ses hydrates, en particulier l'olodatérol et le chlorhydrate d'olodatérol
CY1114238T1 (el) 2,4 – δι (φαινυλαμινο) - πυριμιδινες χρησιμες στην αντιμετωπιση των νεοπλασματικων παθησεων, των φλεγμονωδων διαταραχων και των διαταραχων του ανοσοποιητικου συστηματος
UY27222A1 (es) Pirazolopirimidinas como agentes terapéuticos
SE0202463D0 (sv) Novel compounds
DK1178958T3 (da) N-cyanomethylamider som proteaseinhibitorer
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
NO20063231L (no) Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
SE0302487D0 (sv) Novel compounds
CY1109722T1 (el) Ενδιαμεσες ενωσεις για την παρασκευη της trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,73oxepino[4,5-c]pyrrole
NZ543186A (en) Reverse-turn mimetics and method relating thereto
DK1556371T3 (da) Benzimidazol-derivater og deres anvendelse som prodrugs for protonpumpe-inhibitorer
SE0302324D0 (sv) Novel compounds
SE0302323D0 (sv) Novel compounds
EA200700144A1 (ru) Производные пиридопиримидина, их получение, их применение в терапии
UY27338A1 (es) Nuevos derivados de ácido sulfónico
EA200500690A1 (ru) Новые соединения пиридопиримидинона, способ их получения и фармацевтические композиции, которые их содержат
AR045727A1 (es) Fluorocombretastatina y derivados de la misma
CA2216664A1 (fr) Nouvelles amines cycliques n-substituees, leur procede de preparation et les compositions pharmaceutiques les renfermant
EA200600833A1 (ru) Тиазолидиноны, их получение и применение как фармацевтических агентов
EA200300272A1 (ru) Новые производные хиназолина, способ их получения и фармацевтические композиции, содержащие их
NO20073549L (no) Fremgangsmate for fremstilling av organiske forbindelser
AR052365A1 (es) Derivados antihelminticos de imidazol-tiazol
ATE540157T1 (de) Lagerstabile, optische aufheller-formulierungen
EA200100825A1 (ru) Новые 1-арил-4-тиотриазины

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FB Suspension of granting procedure